Related Experiment Video
Updated: Jun 10, 2026
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
Antibody guided precision radiation therapy
Erik D Brady1, Diane E Milenic, Martin W Brechbiel
1Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Building 10, Room B3B69, Bethesda, MD 20892Z-1002, USA.
Monoclonal antibody (mAb) technology, originating from hybridoma advancements, offers targeted "magic bullet" therapies. Genetic engineering has overcome many limitations, including immune responses like human anti-murine immunoglobulin antibodies (HAMA), enhancing therapeutic potential.
Area of Science:
- Immunology and Biotechnology
- Cancer Therapeutics
Background:
- Hybridoma technology, pioneered by Kohler and Milstein, enables monoclonal antibody (mAb) production.
- Early mouse mAbs showed therapeutic promise but faced significant clinical limitations.
- Key challenges included immunogenicity (HAMA), poor tumor delivery, and suboptimal effector functions.
Purpose of the Study:
- To review the evolution and challenges of monoclonal antibody (mAb) therapy.
- To highlight strategies employed to overcome limitations in mAb development.
- To discuss advancements in addressing immunogenicity and improving therapeutic efficacy.
Main Methods:
- Review of hybridoma technology and early monoclonal antibody (mAb) research.
- Analysis of pre-clinical and clinical study findings on mAb limitations.
- Examination of genetic engineering and chemical modification techniques for mAb improvement.
Main Results:
- Mouse mAbs faced limitations including human anti-murine immunoglobulin antibodies (HAMA), inadequate tumor targeting, and poor effector function.
- Genetic engineering and chemical modifications have addressed many of these challenges.
- Chimerization and humanization strategies have been successful in mitigating HAMA responses.
Conclusions:
- Monoclonal antibody (mAb) technology has evolved significantly since its inception.
- Engineering strategies have substantially improved the safety and efficacy of therapeutic mAbs.
- Further advancements continue to refine mAb therapy for various diseases.
